GSK Ventures into Sustainable Healthcare with Low Carbon Ventolin Inhaler
GlaxoSmithKline (GSK) is pioneering the shift towards sustainable healthcare by initiating phase III trials for a low carbon Ventolin inhaler. This move could significantly reduce the environmental impact of metered dose inhalers, which are a substantial part of GSK's carbon footprint.
Read more
